^aIQVIA SMART Portal Patient Insights as of June 2026.

^bThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 11 countries (Brazil, Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈12% of this worldwide patient number. This number is composed of the following US approved indications: AD, asthma, BP, COPD, CRSwNP, CSU, PN, and EoE. Data through March 2026.

^c≈96% of commercial AD patients (6+ months of age) nationally are covered for DUPIXENT. ≈89% of commercial AD patient lives have to fail only 1 or 2 prescription topical treatments.

^dMMIT Analysis, May 2026. Analysis included DUPIXENT, tralokinumab, upadacitinib, abrocitinib, labrikizumab, and nemolizumab. 

^eBased on available published commercial UM coverage criteria. 

^fInclusion in AAD and AAAAI/ACAAI AD Guidelines does not denote endorsement or recommendation of product use by AAD and AAAAI/ACAAI.